Should not be used in patients w/ type 1 diabetes. Discontinue use in patients w/ suspected or diagnosed diabetic ketoacidosis (DKA) or lactic acidosis. Caution in patients at higher risk of DKA; do not restart in patients w/ previous DKA. Recommended to monitor ketones (blood ketone levels is preferred to urine) in patients who are hospitalised for major surgical procedures or acute serious medical illnesses. Temporarily discontinue in case of dehydration, complicated UTI, acute serious medical illnesses or w/ conditions that alter renal function. Caution in medicinal products that can acutely impair renal function. Assess GFR before treatment initiation & regularly thereafter. Regular monitoring of cardiac & renal function in patients w/ stable chronic heart failure. Discontinue prior to or at the time of imaging procedure or major surgical procedures; do not restart until ≥48 hr after imaging procedure or surgery or resumption of oral nutrition, provided w/ a stable renal function. Caution in patients w/ known CV disease, on anti-hypertensive therapy w/ a history of hypotension or age ≥75 yr. Caution w/ co-administered medicinal products which may lead to vol depletion in patients ≥75 yr. Cases of lower limb amputation have been observed; counsel patients on routine preventative footcare. Patients w/ suspected Fournier's Gangrene should immediately start treatment w/ broad-spectrum antibiotics &, if necessary, surgical debridement; discontinue Jardiance Duo, closely monitor blood glucose levels, & provide appropriate alternative therapy. Increased haematocrit level w/ empagliflozin. Positive result for glucose in urine test while taking empagliflozin. Should not be initiated in patients w/ GFR <60 mL/min. Not recommended in patients w/ GFR <45 mL/min. Not recommended during pregnancy. Should not be used during breast-feeding. Not recommended in patients ≥85 yr or <18 yr.